후천성 혈우병 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global acquired hemophilia therapeutics market size is expected to reach USD 15.42 Billion in 2034 from USD 8.55 Billion in 2025, growing at a CAGR of 6.77 during 2026-2034.This market has experienced gradual growth due to increasing recognition and diagnosis of acquired hemophilia, a rare bleeding disorder caused by the development of autoantibodies against clotting factors. Improved awareness among healthcare professionals and advancements in treatment protocols have supported market development. Expanding access to specialized care has further enhanced patient management.

Key growth drivers include improvements in diagnostic testing, increasing availability of targeted therapies, and growing healthcare investments. Physicians are adopting advanced treatment approaches aimed at controlling bleeding episodes and addressing underlying immune responses. Research efforts focused on rare disease management have also contributed to the introduction of innovative therapeutic options.

Future prospects remain positive as healthcare systems strengthen rare disease programs and pharmaceutical companies continue developing specialized treatments. Advances in biologic therapies and personalized medicine are expected to improve treatment outcomes. Increased patient awareness and ongoing clinical research will likely support sustained growth in the acquired hemophilia therapeutics market.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Treatment

• On-Demand (Clotting Factor, Replacement Therapy, Desmopressin, Other On-Demand Treatments)
• Prophylaxis (Clotting Factor Replacement Therapy, Gene Therapy, Other Prophylaxis Treatments)

By Type

• Hemophilia A
• Hemophilia B
• Hemophilia C
• Other

By End User

• Hospitals
• Clinic
• Other

COMPANIES PROFILED

• Pfizer Inc., Roche Holding AG, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sanofi SA, GlaxoSmithKline plc, Takeda PharmaceuticalCompany Limited, Amgen Inc., Novo Nordisk A/S, Baxter Healthcare Corporation, Teva Pharmaceutical Industries Ltd., Mylan NV, Biogen Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ACQUIRED HEMOPHILIA THERAPEUTICS MARKET: BY TREATMENT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment
• 4.2. On-Demand (Clotting Factor, Replacement Therapy, Desmopressin, Other On-Demand Treatments) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Prophylaxis (Clotting Factor Replacement Therapy, Gene Therapy, Other Prophylaxis Treatments) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ACQUIRED HEMOPHILIA THERAPEUTICS MARKET: BY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. Hemophilia A Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Hemophilia B Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Hemophilia C Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ACQUIRED HEMOPHILIA THERAPEUTICS MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ACQUIRED HEMOPHILIA THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Treatment
  • 7.2.2 By Type
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Treatment
  • 7.3.2 By Type
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Treatment
  • 7.4.2 By Type
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Treatment
  • 7.5.2 By Type
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Treatment
  • 7.6.2 By Type
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ACQUIRED HEMOPHILIA THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Pfizer Inc
  • 9.2.2 Roche Holding AG
  • 9.2.3 Bayer AG
  • 9.2.4 Novartis AG
  • 9.2.5 Bristol-Myers Squibb Company
  • 9.2.6 Sanofi SA
  • 9.2.7 GlaxoSmithKline Plc
  • 9.2.8 Takeda PharmaceuticalCompany Limited
  • 9.2.9 Amgen Inc
  • 9.2.10 Novo Nordisk A/S
  • 9.2.11 Baxter Healthcare Corporation
  • 9.2.12 Teva Pharmaceutical Industries Ltd
  • 9.2.13 Mylan NV
  • 9.2.14 Biogen Inc